Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HJLI Stock Forecast 2025-2026
$3.62
Current Price
$32.37M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HJLI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
HJLI Price Momentum
0.0%
1 Week Change
+35.6%
1 Month Change
-27.7%
1 Year Change
+17.9%
Year-to-Date Change
-44.1%
From 52W High of $6.48
+78.5%
From 52W Low of $2.03
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Hancock Jaffe (HJLI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HJLI and similar high-potential opportunities.
Latest HJLI Stock Price Targets & Analyst Predictions
HJLI has shown a year-to-date change of 17.9% and a 1-year change of -27.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HJLI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HJLI Analyst Ratings
0
Buy
0
Hold
0
Sell
HJLI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.62
Latest HJLI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HJLI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Hancock Jaffe Laboratories Inc (HJLI) Competitors
The following stocks are similar to Hancock Jaffe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hancock Jaffe Laboratories Inc (HJLI) Financial Data
Hancock Jaffe Laboratories Inc has a market capitalization of $32.37M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +14.9%.
Valuation Metrics
Market Cap
$32.37M
Enterprise Value
$23.92M
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+174.2%
Current Ratio
76.2x
Debt/Equity
0.0x
ROE
+14.9%
ROA
-103.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Hancock Jaffe Laboratories Inc (HJLI) Business Model
About Hancock Jaffe Laboratories Inc
What They Do
Business Model
Additional Information
Company Information
Hancock Jaffe Laboratories Inc (HJLI) Latest News & Analysis
Latest News
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
3 years ago
Quick Summary
Hancock Jaffe Laboratories' CEO, Robert Berman, will host a live webinar on September 27, 2021, at 1 PM ET, as part of The Duologue Series by Ladenburg Thalmann.
Why It Matters
The webinar offers insights into Hancock Jaffe's strategy and performance, potentially influencing stock prices and investor sentiment in the medical device sector.
Source: Accesswire
Market Sentiment:
Neutral
Hancock Jaffe To Rebrand As enVVeno Medical
3 years ago
Quick Summary
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will rebrand as enVVeno Medical Corporation (ticker: NVNO) on October 1, focusing solely on the VenoValve for venous disease treatment.
Why It Matters
The name change and strategic focus on the VenoValve may signal a clearer direction and potential growth for enVVeno Medical, influencing investor sentiment and stock performance.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Hancock Jaffe will rebrand as enVVeno Medical Corporation (NASDAQ: NVNO) on October 1, 2021, focusing on venous disease and developing a second product to be revealed in mid-2022.
Why It Matters
Hancock Jaffe's rebranding and focus on venous disease signal a strategic shift that could enhance market positioning and potentially lead to increased investor confidence and value.
Source: Accesswire
Market Sentiment:
Neutral
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
3 years ago
Quick Summary
Hancock Jaffe Laboratories will hold a corporate update conference call with a live video webcast on September 21, 2021, at 4:30 p.m. ET.
Why It Matters
The conference call indicates Hancock Jaffe's commitment to transparency and may reveal key developments that could impact stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Hancock Jaffe Laboratories, focused on bioprosthetics for cardiovascular diseases, received IDE approval in April 2021 to start a pivotal trial for its VenoValve in the U.S.
Why It Matters
Hancock Jaffe's IDE approval for the pivotal trial of VenoValve signals potential market entry and revenue growth, impacting stock value and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Hancock Jaffe Laboratories (NASDAQ: HJLI) has secured a $20 million investment from Perceptive Advisors through a registered direct offering, selling 2,540,650 shares at $7.8720 each.
Why It Matters
Hancock Jaffe's $20 million stock offering enhances liquidity and may bolster growth prospects, impacting its market valuation and investor sentiment in the life sciences sector.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About HJLI Stock
What is Hancock Jaffe Laboratories Inc's (HJLI) stock forecast for 2025?
Analyst forecasts for Hancock Jaffe Laboratories Inc (HJLI) are not currently available. The stock is trading at $3.62.
Is HJLI stock a good investment in 2025?
Analyst ratings for HJLI are not currently available. The stock is currently trading at $3.62. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HJLI stock?
Price predictions from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.62.
What is Hancock Jaffe Laboratories Inc's business model?
N/A
What is the highest forecasted price for HJLI Hancock Jaffe Laboratories Inc?
Price targets from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.62.
What is the lowest forecasted price for HJLI Hancock Jaffe Laboratories Inc?
Price targets from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.62.
What is the overall HJLI consensus from analysts for Hancock Jaffe Laboratories Inc?
Analyst ratings for HJLI are not currently available. The stock is trading at $3.62.
How accurate are HJLI stock price projections?
Stock price projections, including those for Hancock Jaffe Laboratories Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 3:18 AM UTC